Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM.

J Clin Oncol. 2019 Mar 10;37(8):658-667. doi: 10.1200/JCO.18.00050. Epub 2019 Feb 1.

PMID:
30707660
2.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
3.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group.

N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.

PMID:
30575490
4.

Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes.

Soler A, Cayrefourcq L, Mazard T, Babayan A, Lamy PJ, Assou S, Assenat E, Pantel K, Alix-Panabières C.

Sci Rep. 2018 Oct 29;8(1):15931. doi: 10.1038/s41598-018-34365-z.

5.

A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort.

Canivet C, Gourgou-Bourgade S, Napoléon B, Palazzo L, Flori N, Guibert P, Piessen G, Farges-Bancel D, Seitz JF, Assenat E, Vendrely V, Truant S, Vanbiervliet G, Berthelémy P, Garcia S, Gomez-Brouchet A, Buscail L, Bournet B; BACAP Consortium.

BMC Cancer. 2018 Oct 16;18(1):986. doi: 10.1186/s12885-018-4906-4.

6.

Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.

Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, Ursic-Bedoya J, Pageaux GP, Mariano-Goulart D, Aho S, Guiu B.

J Vasc Interv Radiol. 2018 Dec;29(12):1662-1670.e4. doi: 10.1016/j.jvir.2018.07.006. Epub 2018 Sep 11.

PMID:
30217745
7.

Percutaneous thermal ablation of hepatocellular carcinomas located in the hepatic dome using artificial carbon dioxide pneumothorax: retrospective evaluation of safety and efficacy.

Hermida M, Cassinotto C, Piron L, Assenat E, Pageaux GP, Escal L, Pierredon-Foulongne MA, Verzilli D, Jaber S, Guiu B.

Int J Hyperthermia. 2018 Dec;35(1):90-96. doi: 10.1080/02656736.2018.1477206. Epub 2018 Jun 20.

PMID:
29923441
8.

Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.

Kudo M, Kang YK, Park JW, Qin S, Inaba Y, Assenat E, Umeyama Y, Lechuga MJ, Valota O, Fujii Y, Martini JF, Williams JA, Obi S.

Liver Cancer. 2018 May;7(2):148-164. doi: 10.1159/000484620. Epub 2017 Dec 8.

9.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
10.

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.

Walter T, Malka D, Hentic O, Lombard-Bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz JE, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec JY, Lepage C.

Dig Liver Dis. 2018 Feb;50(2):195-198. doi: 10.1016/j.dld.2017.11.020. Epub 2017 Dec 6.

PMID:
29258812
11.

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group.

Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.

PMID:
29107679
12.

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.

Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M.

Ann Oncol. 2017 Sep 1;28(9):2149-2159. doi: 10.1093/annonc/mdx330.

PMID:
28911069
13.

Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.

Prieur A, Cappellini M, Habif G, Lefranc MP, Mazard T, Morency E, Pascussi JM, Flacelière M, Cahuzac N, Vire B, Dubuc B, Durochat A, Liaud P, Ollier J, Pfeiffer C, Poupeau S, Saywell V, Planque C, Assenat E, Bibeau F, Bourgaux JF, Pujol P, Sézeur A, Ychou M, Joubert D.

Clin Cancer Res. 2017 Sep 1;23(17):5267-5280. doi: 10.1158/1078-0432.CCR-17-0533. Epub 2017 Jun 9.

14.

SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques.

Riou O, Llacer Moscardo C, Fenoglietto P, Deshayes E, Tetreau R, Molinier J, Lenglet A, Assenat E, Ychou M, Guiu B, Aillères N, Bedos L, Azria D.

Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):103-110. doi: 10.1016/j.rpor.2017.02.006. Epub 2017 Apr 6.

15.

[Portal vein embolization: Present and future].

Piron L, Deshayes E, Escal L, Souche R, Herrero A, Pierredon-Foulongne MA, Assenat E, le Lam N, Quenet F, Guiu B.

Bull Cancer. 2017 May;104(5):407-416. doi: 10.1016/j.bulcan.2017.03.009. Epub 2017 May 3. Review. French.

PMID:
28477870
16.

Correction: The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner.

Arsic N, Ho-Pun-Cheung A, Lopez-Crapez E, Assenat E, Jarlier M, Anguille C, Colard M, Pezet M, Roux P, Gadea G.

PLoS One. 2017 Apr 6;12(4):e0175607. doi: 10.1371/journal.pone.0175607. eCollection 2017.

17.

The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner.

Arsic N, Ho-Pun-Cheung A, Evelyne C, Assenat E, Jarlier M, Anguille C, Colard M, Pezet M, Roux P, Gadea G.

PLoS One. 2017 Feb 17;12(2):e0172125. doi: 10.1371/journal.pone.0172125. eCollection 2017. Erratum in: PLoS One. 2017 Apr 6;12 (4):e0175607.

18.

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM.

J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26.

19.

Molecular Portrait of Metastasis-Competent Circulating Tumor Cells in Colon Cancer Reveals the Crucial Role of Genes Regulating Energy Metabolism and DNA Repair.

Alix-Panabières C, Cayrefourcq L, Mazard T, Maudelonde T, Assenat E, Assou S.

Clin Chem. 2017 Mar;63(3):700-713. doi: 10.1373/clinchem.2016.263582. Epub 2016 Dec 22.

20.

Interventional oncology for hepatocellular carcinoma.

Delicque J, Boulin M, Guiu B, Pelage JP, Escal L, Schembri V, Assenat E, Fohlen A.

Clin Res Hepatol Gastroenterol. 2016 Nov;40(5):530-537. doi: 10.1016/j.clinre.2016.01.007. Epub 2016 Apr 4. Review.

PMID:
27055387
21.

NOD1 Participates in the Innate Immune Response Triggered by Hepatitis C Virus Polymerase.

Vegna S, Gregoire D, Moreau M, Lassus P, Durantel D, Assenat E, Hibner U, Simonin Y.

J Virol. 2016 Jun 10;90(13):6022-6035. doi: 10.1128/JVI.03230-15. Print 2016 Jul 1.

22.

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.

Bournet B, Muscari F, Buscail C, Assenat E, Barthet M, Hammel P, Selves J, Guimbaud R, Cordelier P, Buscail L.

Clin Transl Gastroenterol. 2016 Mar 24;7:e157. doi: 10.1038/ctg.2016.18.

23.

Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses.

Nougaret S, Vargas HA, Lakhman Y, Sudre R, Do RK, Bibeau F, Azria D, Assenat E, Molinari N, Pierredon MA, Rouanet P, Guiu B.

Radiology. 2016 Aug;280(2):446-54. doi: 10.1148/radiol.2016150702. Epub 2016 Feb 26.

24.

Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.

Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, Mollevi C, Senesse P.

Cancer Med. 2016 Apr;5(4):607-16. doi: 10.1002/cam4.621. Epub 2016 Jan 27.

25.

A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasm.

Khemissa F, Mineur L, Amsellem C, Assenat E, Ramdani M, Bachmann P, Janiszewski C, Cristiani I, Collin F, Courraud J, de Forges H, Dechelotte P, Senesse P.

Dig Liver Dis. 2016 Mar;48(3):327-32. doi: 10.1016/j.dld.2015.11.025. Epub 2015 Dec 15.

PMID:
26776879
26.

Feasibility and tolerability of self-insertion of a transnasal tube for esophagogastroduodenoscopy: a pilot study.

Senesse P, Georges G, Séville S, Flori N, Stoebner A, Assenat E, de Forges H.

Endoscopy. 2015;47 Suppl 1 UCTN:E475-6. doi: 10.1055/s-0034-1392795. Epub 2015 Oct 19. No abstract available.

PMID:
26479292
27.

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.

Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A.

Oncotarget. 2015 May 20;6(14):12796-808.

28.

Reply to: "arginase 1: a potential marker of a common pattern of liver steatosis in HCV and NAFLD children".

Assenat E, Akkari L, Moreau M, Hibner U.

J Hepatol. 2015 May;62(5):1208-9. doi: 10.1016/j.jhep.2015.02.002. Epub 2015 Feb 9. No abstract available.

29.

Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship.

Carenco C, Assenat E, Faure S, Duny Y, Danan G, Bismuth M, Herrero A, Jung B, Ursic-Bedoya J, Jaber S, Larrey D, Navarro F, Pageaux GP.

Am J Transplant. 2015 Mar;15(3):678-86. doi: 10.1111/ajt.13018. Epub 2015 Feb 3.

30.

Establishment and characterization of a cell line from human circulating colon cancer cells.

Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K, Alix-Panabières C.

Cancer Res. 2015 Mar 1;75(5):892-901. doi: 10.1158/0008-5472.CAN-14-2613. Epub 2015 Jan 15.

31.

Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors.

Carenco C, Faure S, Herrero A, Assenat E, Duny Y, Danan G, Bismuth M, Chanques G, Ursic-Bedoya J, Jaber S, Larrey D, Navarro F, Pageaux GP.

Liver Int. 2015 Jun;35(6):1748-55. doi: 10.1111/liv.12758. Epub 2015 Jan 21.

32.

Bone metastases in gastrointestinal cancer.

Portales F, Thézenas S, Samalin E, Assenat E, Mazard T, Ychou M.

Clin Exp Metastasis. 2015 Jan;32(1):7-14. doi: 10.1007/s10585-014-9686-x. Epub 2014 Nov 9.

PMID:
25381591
33.

MR imaging of locally advanced low rectal cancer: Relationships between imaging findings and the pathological tumor regression grade.

Fujii S, Nougaret S, Escal L, Azria D, Assenat E, Rouanet P, Reinhold C, Guiu B.

J Magn Reson Imaging. 2015 Aug;42(2):421-6. doi: 10.1002/jmri.24783. Epub 2014 Oct 29.

PMID:
25351373
34.

Hepatitis C viral proteins perturb metabolic liver zonation.

Moreau M, Rivière B, Vegna S, Aoun M, Gard C, Ramos J, Assenat E, Hibner U.

J Hepatol. 2015 Feb;62(2):278-85. doi: 10.1016/j.jhep.2014.09.004. Epub 2014 Sep 16.

PMID:
25220251
35.

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT.

JAMA. 2014 Jul 2;312(1):57-67. doi: 10.1001/jama.2014.7189.

PMID:
25058218
36.

A new suturing procedure for closure of a gastrocutaneous fistula.

Flori N, Courraud J, Assenat E, Senesse P.

Endoscopy. 2014;46 Suppl 1 UCTN:E258-9. doi: 10.1055/s-0034-1365433. Epub 2014 May 22. No abstract available.

PMID:
24853447
37.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; BINGO investigators.

Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19.

38.

Characterization of a novel PXR isoform with potential dominant-negative properties.

Breuker C, Planque C, Rajabi F, Nault JC, Couchy G, Zucman-Rossi J, Evrard A, Kantar J, Chevet E, Bioulac-Sage P, Ramos J, Assenat E, Joubert D, Pannequin J, Hollande F, Pascussi JM.

J Hepatol. 2014 Sep;61(3):609-16. doi: 10.1016/j.jhep.2014.04.030. Epub 2014 May 2.

PMID:
24798619
39.

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.

Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T.

Br J Cancer. 2014 Mar 4;110(5):1148-54. doi: 10.1038/bjc.2013.813. Epub 2014 Jan 9.

40.

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.

J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26.

PMID:
23980090
41.

Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.

Mazard T, Causse A, Simony J, Leconet W, Vezzio-Vie N, Torro A, Jarlier M, Evrard A, Del Rio M, Assenat E, Martineau P, Ychou M, Robert B, Gongora C.

Mol Cancer Ther. 2013 Oct;12(10):2121-34. doi: 10.1158/1535-7163.MCT-12-0966. Epub 2013 Aug 19.

42.

A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.

Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, Letoublon C, Guimbaud R, Francois E, Ducreux M, Desseigne F, Fabre JM, Assenat E.

Ann Surg Oncol. 2013 Dec;20(13):4289-97. doi: 10.1245/s10434-013-3217-x. Epub 2013 Aug 17.

PMID:
23955585
43.

Applying ecological and evolutionary theory to cancer: a long and winding road.

Thomas F, Fisher D, Fort P, Marie JP, Daoust S, Roche B, Grunau C, Cosseau C, Mitta G, Baghdiguian S, Rousset F, Lassus P, Assenat E, Grégoire D, Missé D, Lorz A, Billy F, Vainchenker W, Delhommeau F, Koscielny S, Itzykson R, Tang R, Fava F, Ballesta A, Lepoutre T, Krasinska L, Dulic V, Raynaud P, Blache P, Quittau-Prevostel C, Vignal E, Trauchessec H, Perthame B, Clairambault J, Volpert V, Solary E, Hibner U, Hochberg ME.

Evol Appl. 2013 Jan;6(1):1-10. doi: 10.1111/eva.12021. Epub 2012 Nov 16.

44.

Preventive evolutionary medicine of cancers.

Hochberg ME, Thomas F, Assenat E, Hibner U.

Evol Appl. 2013 Jan;6(1):134-43. doi: 10.1111/eva.12033. Epub 2012 Dec 5.

45.

Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer.

Ho-Pun-Cheung A, Bazin H, Gaborit N, Larbouret C, Garnero P, Assenat E, Castan F, Bascoul-Mollevi C, Ramos J, Ychou M, Pèlegrin A, Mathis G, Lopez-Crapez E.

PLoS One. 2012;7(7):e37065. doi: 10.1371/journal.pone.0037065. Epub 2012 Jul 19.

46.

Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication.

Faure S, Herrero A, Jung B, Duny Y, Daures JP, Mura T, Assenat E, Bismuth M, Bouyabrine H, Donnadieu-Rigole H, Navarro F, Jaber S, Larrey D, Pageaux GP.

J Hepatol. 2012 Aug;57(2):306-12. doi: 10.1016/j.jhep.2012.03.014. Epub 2012 Apr 17.

PMID:
22521352
47.

Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.

Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E.

World J Gastroenterol. 2012 Mar 28;18(12):1357-64. doi: 10.3748/wjg.v18.i12.1357.

48.

Immunonutrition before and during radiochemotherapy: improvement of inflammatory parameters in head and neck cancer patients.

Machon C, Thezenas S, Dupuy AM, Assenat E, Michel F, Mas E, Senesse P, Cristol JP.

Support Care Cancer. 2012 Dec;20(12):3129-35. doi: 10.1007/s00520-012-1444-5. Epub 2012 Mar 28.

PMID:
22453793
49.

MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy.

Nougaret S, Rouanet P, Molinari N, Pierredon MA, Bibeau F, Azria D, Lemanski C, Assenat E, Duffour J, Ychou M, Reinhold C, Gallix B.

Radiology. 2012 May;263(2):409-18. doi: 10.1148/radiol.12111263. Epub 2012 Mar 21.

PMID:
22438364
50.

KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.

Boissière-Michot F, Lopez-Crapez E, Frugier H, Berthe ML, Ho-Pun-Cheung A, Assenat E, Maudelonde T, Lamy PJ, Bibeau F.

Mod Pathol. 2012 May;25(5):731-9. doi: 10.1038/modpathol.2011.210. Epub 2012 Jan 27.

Supplemental Content

Loading ...
Support Center